Continuing Education Activity

Vasomotor rhinitis is a prevalent form of nonallergic rhinitis that affects millions of individuals. Unlike allergic rhinitis, this condition does not elicit a typical allergic response. Rather, vasomotor rhinitis arises from dysregulation of the autonomic nervous system, leading to atypical responses of the nasal mucosa to various environmental and internal stimuli. The diagnosis of vasomotor rhinitis is one of exclusion, requiring clinicians to eliminate allergic, infectious, and structural causes of nasal symptoms. Patients typically present with chronic nasal congestion, rhinorrhea, and postnasal drip, without significant itching or sneezing. Management strategies for vasomotor rhinitis primarily focus on identifying and avoiding known triggers, as well as pharmacological interventions such as topical intranasal corticosteroids, antihistamines, and anticholinergic agents. This activity reviews the characteristics, etiological factors, recognition, management, and preventive strategies for vasomotor rhinitis, equipping healthcare professionals with the knowledge and resources to deliver optimal patient care through an interprofessional approach.

Objectives:

• Assess patients with nasal hyperresponsiveness lacking a clear symptom etiology.
• Develop diagnostic strategies to differentiate vasomotor rhinitis from other forms of rhinitis, including nonallergic, allergic, and infectious types.
• Develop and implement therapeutic strategies for treating patients with vasomotor rhinitis.
• Communicate diagnostic reasoning, treatment goals, and follow-up plans among allergists, otolaryngologists, primary care clinicians, pharmacists, and other members of the interprofessional healthcare team.

Access free multiple choice questions on this topic.

Introduction

Rhinitis is defined as inflammation of the nasal mucosa characterized by rhinorrhea, sneezing, nasal congestion, and itchiness, lasting for 2 or more consecutive days and occurring for more than an hour on most days.[1] Rhinitis is estimated to affect nearly one-third of the total population.[2] Various classifications have been used to describe rhinitis, including 3 main categories: allergic, infectious, and nonallergic. Nonallergic conditions that may cause similar symptoms may overlap with allergic and infectious causes. Nonallergic causes may include physical agents, including occupational and environmental toxins, drug-induced rhinitis, including aspirin and other medications, hormonal imbalance, and other causes, including nonallergic rhinitis with eosinophilia syndrome, irritants, food, emotional factors, atrophic rhinitis, and idiopathic rhinitis.[3] The differential diagnosis of rhinitis is extensive, ranging from mechanical and structural issues, such as a deviated septum and nasal polyps, to infections, tumors, granulomas, including granulomatosis with polyangiitis, sarcoidosis, and ciliary defects.[4] Despite the best diagnostic efforts, an estimated half of patients with nonallergic rhinitis lack a clear cause for their symptoms; these cases are termed idiopathic rhinitis.[5]

Vasomotor rhinitis is a type of idiopathic rhinitis characterized by abnormal regulation of the nasal blood vessels and nerves. Various factors, including temperature changes, strong odors, smoke, alcohol, and spicy foods, can trigger this condition. Common symptoms of vasomotor rhinitis include rhinorrhea and nasal congestion; however, pruritus or sneezing may or may not occur.

Establishing a definitive diagnosis requires a careful history, physical examination, and diagnostic testing. Treatment can be challenging and should focus on the presenting symptoms. Therapy generally involves avoiding known triggers and may include medical therapy as an adjunct.[6][7] Surgical options often improve symptoms but typically do not eliminate them. The pathophysiology of nonallergic rhinitis is complex and remains incompletely understood. Researchers theorize that nonallergic rhinitis results partly from an imbalance between parasympathetic and sympathetic inputs to the nasal mucosa.[8] This activity reviews the characteristics, diagnostic and therapeutic challenges, pathogenesis, and epidemiology of vasomotor rhinitis.

Etiology

Although the etiology of vasomotor rhinitis remains poorly understood, researchers suspect an association with dysregulation of the sympathetic, parasympathetic, and nociceptive nerves innervating the nasal mucosa.[8] The imbalance among mediators leads to increased vascular permeability and mucus secretion from the submucosal nasal glands.[9][10] The parasympathetic nervous system primarily regulates mucous secretion, whereas the sympathetic nervous system controls vascular tone.[11] Acetylcholine is the primary parasympathetic neurotransmitter that regulates mucus secretion and rhinorrhea. Norepinephrine and neuropeptide Y are sympathetic neurotransmitters that control vascular tone in the nasal mucosa and modulate secretions initiated by the parasympathetic system.[12] Sensory neuropeptides and nociceptive type C fibers of the trigeminal nerve contribute to mast cell degranulation and itching and sneezing reflexes.[8]

Epidemiology

Rhinitis, whether allergic or nonallergic, affects about 20% of the population in industrialized countries.[13] Allergic rhinitis affects an estimated 20 to 40 million people and costs more than US $1.9 billion annually.[14] Nonallergic rhinitis, including vasomotor rhinitis, typically presents later in life, with symptoms most commonly occurring between 30 and 60 years of age.[13] Women are more commonly affected by nonallergic rhinitis than men. Among women aged 50 to 64, 70% experience some form of nonallergic rhinitis in any given year.[15] Additionally, tobacco smoking is associated with an increased risk of vasomotor rhinitis.[16] Results from recent studies have established a causal relationship between specific gut microbiome composition and an increased risk of developing vasomotor rhinitis.[17]

Pathophysiology

In contrast to allergic rhinitis, the pathophysiology of vasomotor rhinitis and nonallergic rhinitis is not mediated by immunoglobulin E (IgE)–mediated allergic responses.[18] However, patients with vasomotor rhinitis may have some similar symptoms, such as congestion and rhinorrhea, resulting from multiple mechanisms.[18] Patients with vasomotor rhinitis may have an imbalance in cholinergic, adrenergic, and nociceptive pathways.[18] In addition to an autonomic nervous system imbalance, a hyperreactive nasal mucosal environment is thought to contribute to vasomotor rhinitis, leading to the inappropriate release of chemical mediators such as substance P, calcitonin gene-related peptide, and neurokinin.[17] Overexpression of transient receptor potential ion channels has also been implicated in the disease.[18]

History and Physical

Vasomotor rhinitis is often diagnosed by excluding other conditions. A thorough history, comprehensive head and neck examination, and appropriate diagnostic testing help rule out infections, allergies, and other inflammatory causes.[19] Symptoms of both allergic and nonallergic rhinitis include headaches, facial pressure, postnasal drip, coughing, and throat clearing.[6] Patients with vasomotor rhinitis can typically be divided into 2 groups based on their predominant symptoms: blockers, who experience congestion, and runners, who have rhinorrhea. Individuals with rhinorrhea often exhibit an increased cholinergic response, whereas those with nasal obstruction tend to have nociceptive neurons that are more sensitive to innocuous stimuli.[6][19] Vasomotor rhinitis is typically a perennial condition, meaning the condition is present year-round. However, vasomotor rhinitis can have seasonal exacerbations due to changes in barometric pressure, temperature, and humidity, which may be mistaken for allergic rhinitis.

Environmental triggers for individuals with vasomotor rhinitis can include strong odors, exposure to cold air, alcohol consumption, and spicy foods. Physical examination often reveals swollen, boggy mucosa with clear, mucoid secretions. Additionally, mucosal injection and lymphoid hyperplasia in the tonsils, adenoids, and lingual tonsils may be observed. In cases of chemical sensitivities, blanched mucosa has been reported surrounding prominent blood vessels.[20] Examination of the nasal cavity and nasopharynx may help identify primary or secondary causes of rhinitis. For example, purulent drainage from the middle meatus on nasal endoscopy would indicate an infectious process, essentially ruling out vasomotor rhinitis.

Evaluation

The workup for vasomotor rhinitis should include skin testing, serum-specific IgE antibody testing, or both. Because vasomotor rhinitis is a diagnosis of exclusion, skin test and serum antibody test results are typically negative for relevant allergens. Nasal cytology can provide information about the cell types that compose the mucosa and help identify inflammatory markers. Scrapings from the inferior turbinate, nasal lavage, or nose blowing can provide epithelial cells for analysis. The presence of 5 to 25 eosinophils in high-power fields is compatible with the diagnosis of nonallergic rhinitis with eosinophilia syndrome, a subset of nonallergic rhinitis.[21] Brandt and Bernstein developed a validated questionnaire to aid in diagnosing vasomotor rhinitis. Results from their study revealed that patients with symptom onset after 35 years of age, a negative family history of allergies or atopy, no outdoor or cat-related symptoms, and symptoms associated with exposure to perfumes and fragrances had a 96% likelihood of vasomotor rhinitis.[22]

Nasal provocation testing has become standardized through the use of commercially available products. Provocation testing involves exposing a patient to the relevant allergen, assessing the clinical response, and collecting objective data using rhinomanometry and acoustic rhinometry.[23] Computed tomography of the paranasal sinuses is a diagnostic option for patients with suspected sinus disease, and magnetic resonance imaging can assist in evaluating suspected head and neck mass lesions. However, imaging is rarely helpful in cases of vasomotor rhinitis.

Distinguishing vasomotor rhinitis from allergic rhinitis can be challenging. Symptoms and physical examination findings are often very similar. Allergic rhinitis is a nasal disorder characterized by an IgE–mediated inflammatory response triggered by exposure to an allergen. The timing of symptoms provides clues to differentiate between nonallergic and allergic rhinitis. Seasonal pollen peaks, exposure to pet dander or mold spores, and geographic relocation that leads to symptoms can point to a diagnosis of allergic rhinitis. The patient’s history provides essential information for diagnosis. Allergy testing is a clinically useful tool for identifying a specific allergen and guiding treatment. Allergy testing alone can be nonspecific, but when combined with a thorough history and physical examination, it can help distinguish vasomotor rhinitis from allergic rhinitis.[2]  

A detailed history will often help distinguish an infectious process from an allergic process. Infectious rhinitis also presents with symptoms similar to those of nonallergic rhinitis, including nasal purulence, postnasal drip, facial pressure and pain, fever, and sore throat. The 3 cardinal symptoms of infectious rhinitis are purulent nasal discharge, nasal obstruction, and facial pressure, which are often present for 10 days or longer. A fever may be present or absent, depending on the acuity of the infection, and fever is only 50% sensitive and specific.[24] A physical examination will often reveal purulence in the middle meatus, with hyperemia, edema, or crusting along the middle turbinate.

Treatment / Management

Upon diagnosing vasomotor rhinitis, patient education on avoiding environmental triggers is critical.[6] Avoiding or limiting exposure to inciting factors such as perfumes, tobacco smoke, and cleaning supplies can significantly reduce symptoms. Trigger avoidance is generally feasible, but when they are unavoidable, inciting exposures are an option.[8] A stepwise pharmacologic approach is often used, with the initial intervention targeting the predominant symptom.[6] Topical nasal corticosteroids are considered first-line in vasomotor rhinitis, especially for congestion and obstructive symptoms. Topical corticosteroids act on the nasal mucosa, decreasing neutrophil and eosinophil chemotaxis, reducing mast cell and basophil mediator release, and ultimately decreasing edema and inflammation.[25] Topical corticosteroids are generally well tolerated, and adverse effects are infrequent. The most commonly reported adverse effects are nasal dryness, crusting, and septal irritation.[26] Results from multiple studies showed the effectiveness of topical nasal corticosteroids in treating vasomotor rhinitis. Results from an integrated analysis of 3 double-blind randomized controlled trials demonstrated that fluticasone 200 or 400 μg was significantly more effective than placebo.[27] Fluticasone propionate and beclomethasone are currently the only topical corticosteroid preparations approved by the US Food and Drug Administration (FDA) for the treatment of vasomotor rhinitis.[8][27][28] Results from studies showed that budesonide is efficacious and is currently the only topical corticosteroid with a pregnancy category B rating.[29][30]

Anticholinergic medications can provide relief from unrelenting rhinorrhea. However, the oral preparations have undesirable systemic adverse effects, such as blurred vision, dry mouth, and thickened secretions. A topical anticholinergic, such as ipratropium bromide, is the first choice for rhinorrhea. Results from 2 separate randomized controlled trials demonstrated the effectiveness of ipratropium bromide in controlling rhinorrhea.[31][32] Topical anticholinergics act locally and block parasympathetic input only to the nasal mucosal glands.[31] Systemic adverse effects are uncommon, but epistaxis and nasal dryness may occur.[32] Ipratropium bromide also carries a pregnancy category B rating and can be used in children as young as 6 years.

Oral antihistamines have a limited role in vasomotor rhinitis, with no specific formulation approved. These medications tend to benefit only patients with a sneezing and itching component. Topical antihistamines such as azelastine, an H₁ receptor antagonist, have approval for both allergic and nonallergic rhinitis. Azelastine is helpful in patients with rhinorrhea and nasal congestion. The medication also inhibits leukotriene, kinin, and cytokine synthesis, as well as adhesion molecule expression, while exerting anti-inflammatory effects independent of histamine.[33][34][35][34] This anti-inflammatory activity makes azelastine effective in treating vasomotor rhinitis. Azelastine significantly reduces vasomotor symptoms, including nasal obstruction, rhinorrhea, and nasal edema, as demonstrated in 2 randomized controlled trials.[36][37] Results from these trials demonstrated significant improvement in all symptoms within the first week of treatment. Azelastine is well tolerated, with low discontinuation rates.[36][37] Patients with chronic vasomotor rhinitis are generally less responsive to pharmacologic therapy than patients with allergic rhinitis. The combination of intranasal corticosteroids and topical antihistamines has been effective in treating the symptomatology of chronic nonallergic rhinitis.[38]

Topical capsaicin has also demonstrated efficacy as an adjunctive therapy for rhinorrhea and nasal congestion.[39] The mechanism is thought to center on the modulation of type C fibers associated with nociceptive neurons. Capsaicin targets the transient receptor potential vanilloid 1 ion channel, which is present on epithelial cells, submucosal glands, and nerves in the human nasal mucosa, and helps regulate nasal secretions and congestion. Repeated intranasal applications of capsaicin can desensitize transient receptor potential vanilloid 1, reducing its sensitivity to physical and chemical nociceptive stimuli. However, patients’ tolerance to capsaicin's irritant properties limits its use.[40]

Sympathomimetic medications, specifically topical decongestants, can provide short-term symptomatic relief. Topical decongestants work primarily by stimulating α1 and α2 adrenoreceptors on the vasculature of the nasal mucosa. Receptor stimulation leads to vasoconstriction, decreased blood flow, and, subsequently, decreased congestion and rhinorrhea in the nasal cavity. To date, no study has determined the effectiveness of topical decongestants on chronic nonallergic rhinitis. Furthermore, long-term use of topical decongestants can lead to rebound vasodilation and increased congestion. Clinicians term this condition rhinitis medicamentosa, a form of drug-induced rhinitis. Limiting the use of nasal decongestants to 5 days and not exceeding the recommended dosing can help prevent rhinitis medicamentosa and addiction. Please see StatPearls' companion reference, "Rhinitis Medicamentosa," for further information.[41]

Botulinum toxin has also shown potential for treating vasomotor rhinitis through its anticholinergic effects.[11] Botulinum toxin inhibits acetylcholine release from the presynaptic nerve terminal. Injecting botulinum toxin into the inferior and middle turbinates decreases rhinorrhea and nasal mucous gland secretion in patients with vasomotor rhinitis. The improvement is usually short-lived, lasting roughly 4 weeks.[42] Botulinum toxin is considered a safe treatment without significant adverse effects. However, temporary symptom relief may not be a practical option for most patients.[12]

When medical therapy alone does not adequately control vasomotor rhinitis symptoms, surgical interventions may be used. Mucosal-sparing inferior turbinate reduction surgical procedure improves obstructive symptoms and acts synergistically with medical therapies.[43] By improving the nasal airway, decreasing mucosal edema, preserving turbinate function, and reducing obstructive nasal symptoms, topical corticosteroids and antihistamines can reach deeper into the nasal cavity, resulting in greater symptom reduction.[8] The therapeutic transection of the vidian nerve is a well-known surgical option for vasomotor rhinitis. The technique aims to disrupt the autonomic nerve supply to the nasal cavity, thereby reducing nasal secretions.[8] The vidian nerve forms from the confluence of the greater superficial petrosal and deep petrosal nerves. The deep petrosal nerve contains sympathetic fibers. The greater superficial petrosal nerve contains preganglionic parasympathetic secretomotor fibers for the lacrimal, palatine, and nasal mucus glands, as well as the nerves responsible for vasodilating the vessels of the nasal mucosa.[44] The first vidian neurectomy was described by Golding-Wood in 1961 using a transantral approach and carried significant morbidity due to facial numbness, postoperative bleeding, and ocular injuries.[45][46] With the advent of endoscopic techniques, improved visualization of the pterygopalatine fossa has decreased complications associated with neurectomy. Rates of successful rhinitis control and patient satisfaction following endoscopic vidian neurectomy have been reported as high as 91%.[47] Results from a systematic review by Marshak et al found that all published case series of vidian neurectomy reported improvement in rhinorrhea and nasal congestion.[44] The most notable complications associated with neurectomy include postoperative dry eyes from decreased lacrimation (reported aggregate rate: 48%), dysesthesia, and mucosal engorgement when supine.[10][46] Most symptoms were temporary, with dry eyes resolving in 1 to 6 months.[8][44] Regarding vidian neurectomy, several surgical techniques exist. Sun et al evaluated outcomes of endoscopic vidian neurectomy and highly selective vidian neurectomy. The authors found more complications with endoscopic vidian neurectomy, such as palatal numbness and dry eye; highly selective vidian neurectomy resulted in a shorter duration of effect.[47]

Treating nonallergic rhinitis in pregnancy and children presents unique challenges. Treatment should first center on conservative therapy. Nasal saline irrigations have essentially no risk and may be helpful. If medications are necessary, several options exist. Diphenhydramine may be an option when needed, although clinicians should use caution in children younger than 2 years and during the first trimester of pregnancy. Ipratropium bromide carries a category B rating and is safe in children as young as 6 years. As discussed above, budesonide is the only topical nasal corticosteroid with a category B rating. Fluticasone is safe to use in patients as young as 4 years. Topical decongestants can be used on a limited basis in children as young as 6 years. Oxymetazoline is the decongestant of choice in both pregnancy and children.[48][49]

Surgical treatment for rhinitis is appropriate in specific circumstances, such as when a patient has a deviated nasal septum, enlarged inferior turbinates, or other conditions that block the nasal airways due to cartilage or bone issues, or when related sinus disease is present. Clinicians should consider surgical procedures only for patients who do not respond to adequate medical therapy and for whom the significance of anatomical variations or sinonasal disease is clear. Examples of situations that may warrant surgical intervention include:

• Inferior turbinate hypertrophy unresponsive to topical or oral medications
• Deviated nasal septum
• Anatomic variations of the bony pyramid of the nose (nontraumatic and traumatic)
• Chronic rhinosinusitis with or without nasal polyposis [50]
• Fungal sinusitis
• Unrelated conditions

  • Cerebrospinal fluid leak
  • Inverted papilloma
  • Granuloma
  • Tumors (benign and malignant)

All patients should be advised by their surgeon that surgical intervention may not alleviate all their rhinitis symptoms. Furthermore, some patients may have mixed rhinitis, which is caused by both IgE-mediated and neurogenic pathophysiologic pathways. Treatment may require addressing both types of rhinitis.[51]

Differential Diagnosis

Primary and secondary causes of nonallergic rhinitis exist. Primary causes include 8 subtypes: drug-induced rhinitis, gustatory rhinitis, hormone-induced rhinitis, nonallergic rhinitis with eosinophilia syndrome, rhinitis of aging, atrophic rhinitis, cerebrospinal fluid leak, and idiopathic nonallergic rhinitis.[19] Secondary causes include granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, relapsing polychondritis, systemic lupus erythematosus, Sjögren disease, autoimmune rhinitis, hypothyroidism, pregnancy, acromegaly, metabolic syndromes, cystic fibrosis, Kartagener syndrome, sarcoidosis, immunodeficiency, amyloidosis, laryngopharyngeal reflux, and chronic fatigue syndrome.[52] 

Additionally, drug-induced rhinitis is often further divided into 3 categories: neurogenic, inflammatory, and idiopathic; numerous medications list rhinitis as an adverse effect. The most notable offenders are antihypertensive medications, erectile dysfunction medications, and some psychiatric medications. Overuse of topical decongestants can lead to rhinitis medicamentosa via a different mechanism. Systemic antihypertensive drugs cause rhinitis through neurogenic mechanisms. These medications induce parasympathetic dominance in the nasal mucosa by inhibiting norepinephrine release, resulting in nasal congestion and rhinorrhea.[3]

Hormone-induced rhinitis is associated with nasal congestion secondary to elevated estrogen and progesterone. Up to 65% of women report nasal congestion at some time during their pregnancy.[53] The mechanism remains under investigation. Findings suggest that a cyclic hormonal pattern or slowly increasing plasma levels can affect the nasal mucosa. The postpartum decrease in estrogen and progesterone correlates with a rapid resolution of rhinitis symptoms.[54]

Occupational rhinitis is nasal irritation and inflammation caused by workplace exposures. Causes of rhinitis in the workplace can be classified as allergic, irritant, or a combination of both. Occupational rhinitis causes are often subdivided into high-molecular-weight compounds, such as plant- or animal-derived proteins, and low-molecular-weight compounds, which are often associated with haptens. Certain occupations are at increased risk, including bakers, livestock breeders, industrial workers, and veterinarians.[55] The diagnosis of occupational rhinitis requires both documentation of rhinitis and causation related to workplace exposure. IgE–specific antibodies are often detected in high-molecular-weight compound exposures, but are less sensitive to low-molecular-weight compounds. Reproduction of nasal symptoms from nasal provocation challenge testing remains the standard of care in diagnosing occupational rhinitis.[56]

Prognosis

Nonallergic rhinitis is a persistent condition that is usually present throughout life, but the prognosis is favorable. Results from a study by Rondon et al that reexamined 180 patients with nonallergic rhinitis 3 to 7 years after initial diagnosis showed that as many as 52% of patients reported worsening of their disease, accompanied by a 12% increase in symptom persistence and a 9% increase in nasal symptom severity.[57] Furthermore, patients with nonallergic rhinitis often developed new comorbidities, the most common of which was asthma. The occurrence of chronic sinusitis also increased among these patients.[58]

Complications

Chronic vasomotor rhinitis symptoms often interfere with work performance and school attendance due to loss of productivity and frequent clinician visits. Chronic nonallergic rhinitis places considerable physical and economic burdens on affected patients. In a survey of patients with rhinitis, 25% reported limiting their occupational or residential choices to reduce rhinitis symptoms.[59] Additionally, medical treatments to control symptoms may prompt undesirable adverse effects, such as nasal dryness, palpitations, epistaxis, and drowsiness. These adverse effects compound the negative impact of nonallergic rhinitis on patients.[60] Chronic nonallergic rhinitis is often associated with other conditions, such as headaches, eustachian tube dysfunction, nasal polyps, obstructive sleep apnea, and chronic cough. These symptoms can significantly complicate treatment and impair quality of life.[52]

Deterrence and Patient Education

Patient education is critical in treating vasomotor rhinitis. Patients with known environmental, nonimmunologic, and irritant triggers should be reminded to avoid exposure to these offending agents. Avoidance of irritating stimuli is the mainstay of treatment. Avoidance measures and medical therapy are often sufficient to reduce most of the symptoms and mucosal disease associated with nonallergic rhinitis. If stimuli are unavoidable, educating patients about pretreatment with topical nasal corticosteroids or antihistamines can limit symptoms.[6][8]

Enhancing Healthcare Team Outcomes

Vasomotor rhinitis is diagnosed by excluding other conditions after a thorough evaluation of the patient's history. Vasomotor rhinitis is the most commonly diagnosed form of nonallergic rhinitis, not necessarily because of its high prevalence, but often because healthcare professionals either do not conduct a comprehensive evaluation or test results are inconclusive. Both allergic and nonallergic rhinitis present with similar symptoms, including nasal congestion, runny nose (rhinorrhea), facial pressure, and headaches. Clinicians typically distinguish these conditions by the IgE test result. However, not all patients with allergic rhinitis exhibit an IgE-mediated inflammatory response, leading to considerable overlap among nasal conditions and symptoms. Furthermore, skin and serum allergy tests are often inadequate for diagnosing local allergic rhinitis. Therefore, treating patients with vasomotor rhinitis requires a collaborative approach among healthcare professionals to ensure patient-centered care and improve overall outcomes.

Clinicians play a crucial role in the care of patients with both allergic and nonallergic rhinitis. Specialists involved in care may include allergists, otolaryngologists, and primary care clinicians. Rhinitis is a common condition, and most healthcare professionals encounter rhinitis in their practice. When the diagnosis is complex, specialist consultation may be necessary. As in all areas of health care, coordination among professionals is essential. A strategic approach that incorporates evidence-based strategies is vital, ensuring that informed consent is obtained and that patient autonomy is respected in treatment decisions. Each healthcare professional must understand their responsibilities and contribute their unique expertise to the patient’s care plan, fostering an interdisciplinary approach. Effective communication among professionals is crucial to prevent duplicate treatments and minimize patient frustration. Additionally, care coordination plays a pivotal role in ensuring that the patient's journey from diagnosis to treatment and follow-up is well treated, relevant to individual patient needs, and enhances patient safety. By embracing these principles of clinical skill, knowledge, strategy, ethics, interpersonal communication, and care coordination, healthcare professionals can deliver patient-centered care, ultimately improving patient outcomes and enhancing team performance in the treatment of vasomotor rhinitis.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Weldon D. Diagnosis and management of rhinitis. Prim Care. 1998 Dec;25(4):831-48. [PMC free article: PMC7173193] [PubMed: 9735122]

2.

Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, Zuberbier T, Baena-Cagnani CE, Canonica GW, van Weel C, Agache I, Aït-Khaled N, Bachert C, Blaiss MS, Bonini S, Boulet LP, Bousquet PJ, Camargos P, Carlsen KH, Chen Y, Custovic A, Dahl R, Demoly P, Douagui H, Durham SR, van Wijk RG, Kalayci O, Kaliner MA, Kim YY, Kowalski ML, Kuna P, Le LT, Lemiere C, Li J, Lockey RF, Mavale-Manuel S, Meltzer EO, Mohammad Y, Mullol J, Naclerio R, O'Hehir RE, Ohta K, Ouedraogo S, Palkonen S, Papadopoulos N, Passalacqua G, Pawankar R, Popov TA, Rabe KF, Rosado-Pinto J, Scadding GK, Simons FE, Toskala E, Valovirta E, van Cauwenberge P, Wang DY, Wickman M, Yawn BP, Yorgancioglu A, Yusuf OM, Zar H, Annesi-Maesano I, Bateman ED, Ben Kheder A, Boakye DA, Bouchard J, Burney P, Busse WW, Chan-Yeung M, Chavannes NH, Chuchalin A, Dolen WK, Emuzyte R, Grouse L, Humbert M, Jackson C, Johnston SL, Keith PK, Kemp JP, Klossek JM, Larenas-Linnemann D, Lipworth B, Malo JL, Marshall GD, Naspitz C, Nekam K, Niggemann B, Nizankowska-Mogilnicka E, Okamoto Y, Orru MP, Potter P, Price D, Stoloff SW, Vandenplas O, Viegi G, Williams D., World Health Organization. GA(2)LEN. AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008 Apr;63 Suppl 86:8-160. [PubMed: 18331513]

3.

Fokkens WJ. Thoughts on the pathophysiology of nonallergic rhinitis. Curr Allergy Asthma Rep. 2002 May;2(3):203-9. [PMC free article: PMC7089100] [PubMed: 11918861]

4.

Bousquet J, Van Cauwenberge P, Khaltaev N., Aria Workshop Group. World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001 Nov;108(5 Suppl):S147-334. [PubMed: 11707753]

5.

Van Gerven L, Boeckxstaens G, Jorissen M, Fokkens W, Hellings PW. Short-time cold dry air exposure: a useful diagnostic tool for nasal hyperresponsiveness. Laryngoscope. 2012 Dec;122(12):2615-20. [PubMed: 22865676]

6.

Pattanaik D, Lieberman P. Vasomotor rhinitis. Curr Allergy Asthma Rep. 2010 Mar;10(2):84-91. [PubMed: 20425499]

7.

Kaliner MA. The treatment of vasomotor nonallergic rhinitis. Clin Allergy Immunol. 2007;19:351-62. [PubMed: 17153025]

8.

Yan CH, Hwang PH. Surgical Management of Nonallergic Rhinitis. Otolaryngol Clin North Am. 2018 Oct;51(5):945-955. [PubMed: 29937065]

9.

Bernstein JA. Nonallergic rhinitis: therapeutic options. Curr Opin Allergy Clin Immunol. 2013 Aug;13(4):410-6. [PubMed: 23756873]

10.

Joe SA. Nonallergic rhinitis. Facial Plast Surg Clin North Am. 2012 Feb;20(1):21-30. [PubMed: 22099614]

11.

Shaari CM, Sanders I, Wu BL, Biller HF. Rhinorrhea is decreased in dogs after nasal application of botulinum toxin. Otolaryngol Head Neck Surg. 1995 Apr;112(4):566-71. [PubMed: 7700663]

12.

Ozcan C, Ismi O. Botulinum Toxin for Rhinitis. Curr Allergy Asthma Rep. 2016 Aug;16(8):58. [PubMed: 27461136]

13.

Settipane RA, Charnock DR. Epidemiology of rhinitis: allergic and nonallergic. Clin Allergy Immunol. 2007;19:23-34. [PubMed: 17153005]

14.

Settipane RA, Lieberman P. Update on nonallergic rhinitis. Ann Allergy Asthma Immunol. 2001 May;86(5):494-507; quiz 507-8. [PubMed: 11379801]

15.

Lund VJ, Preziosi P, Hercberg S, Hamoir M, Dubreuil C, Pessey JJ, Stoll D, Zanaret M, Gehanno P. Yearly incidence of rhinitis, nasal bleeding, and other nasal symptoms in mature women. Rhinology. 2006 Mar;44(1):26-31. [PubMed: 16550946]

16.

Wang S, Qi L, Wei H, Jiang F, Yan A. Smoking behavior might affect allergic rhinitis and vasomotor rhinitis differently: A mendelian randomization appraisal. World Allergy Organ J. 2022 Feb;15(2):100630. [PMC free article: PMC8844647] [PubMed: 35228855]

17.

Lin X, Hu X, Zhang J, Luo J, Qin G, Jiang L. Gut microbiota, allergic rhinitis, vasomotor rhinitis, Mendelian randomization, causal association. Braz J Otorhinolaryngol. 2024 Nov-Dec;90(6):101491. [PMC free article: PMC11409179] [PubMed: 39243698]

18.

Aldawas G, Bhat IN. Vasomotor Rhinitis: Current Concepts and Emerging Therapies. Cureus. 2025 Oct;17(10):e95631. [PMC free article: PMC12570286] [PubMed: 41169602]

19.

Kaliner MA. Classification of Nonallergic Rhinitis Syndromes With a Focus on Vasomotor Rhinitis, Proposed to be Known henceforth as Nonallergic Rhinopathy. World Allergy Organ J. 2009 Jun 15;2(6):98-101. [PMC free article: PMC3650985] [PubMed: 24229372]

20.

Meggs WJ, Cleveland CH. Rhinolaryngoscopic examination of patients with the multiple chemical sensitivity syndrome. Arch Environ Health. 1993 Jan-Feb;48(1):14-8. [PubMed: 8452394]

21.

Greiner AN, Meltzer EO. Pharmacologic rationale for treating allergic and nonallergic rhinitis. J Allergy Clin Immunol. 2006 Nov;118(5):985-98. [PubMed: 17088121]

22.

Brandt D, Bernstein JA. Questionnaire evaluation and risk factor identification for nonallergic vasomotor rhinitis. Ann Allergy Asthma Immunol. 2006 Apr;96(4):526-32. [PubMed: 16680922]

23.

Gosepath J, Amedee RG, Mann WJ. Nasal provocation testing as an international standard for evaluation of allergic and nonallergic rhinitis. Laryngoscope. 2005 Mar;115(3):512-6. [PubMed: 15744168]

24.

Rosenfeld RM. CLINICAL PRACTICE. Acute Sinusitis in Adults. N Engl J Med. 2016 Sep 08;375(10):962-70. [PubMed: 27602668]

25.

Pipkorn U, Proud D, Lichtenstein LM, Kagey-Sobotka A, Norman PS, Naclerio RM. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. N Engl J Med. 1987 Jun 11;316(24):1506-10. [PubMed: 2438553]

26.

Cervin A, Andersson M. Intranasal steroids and septum perforation--an overlooked complication? A description of the course of events and a discussion of the causes. Rhinology. 1998 Sep;36(3):128-32. [PubMed: 9830677]

27.

Webb DR, Meltzer EO, Finn AF, Rickard KA, Pepsin PJ, Westlund R, Cook CK. Intranasal fluticasone propionate is effective for perennial nonallergic rhinitis with or without eosinophilia. Ann Allergy Asthma Immunol. 2002 Apr;88(4):385-90. [PubMed: 11995670]

28.

Synnerstad B, Lindqvist N. A clinical comparison of intranasal budesonide with beclomethasone dipropionate for perennial non-allergic rhinitis: a 12 month study. Br J Clin Pract. 1996 Oct-Nov;50(7):363-6. [PubMed: 9015907]

29.

Creticos P, Fireman P, Settipane G, Bernstein D, Casale T, Schwartz H. Intranasal budesonide aqueous pump spray (Rhinocort Aqua) for the treatment of seasonal allergic rhinitis. Rhinocort Aqua Study Group. Allergy Asthma Proc. 1998 Sep-Oct;19(5):285-94. [PubMed: 9801742]

30.

Wight RG, Jones AS, Beckingham E, Andersson B, Ek L. A double blind comparison of intranasal budesonide 400 micrograms and 800 micrograms in perennial rhinitis. Clin Otolaryngol Allied Sci. 1992 Aug;17(4):354-8. [PubMed: 1526057]

31.

Grossman J, Banov C, Boggs P, Bronsky EA, Dockhorn RJ, Druce H, Findlay SR, Georgitis JW, Hampel FC, Kaiser H. Use of ipratropium bromide nasal spray in chronic treatment of nonallergic perennial rhinitis, alone and in combination with other perennial rhinitis medications. J Allergy Clin Immunol. 1995 May;95(5 Pt 2):1123-7. [PubMed: 7538520]

32.

Bronsky EA, Druce H, Findlay SR, Hampel FC, Kaiser H, Ratner P, Valentine MD, Wood CC. A clinical trial of ipratropium bromide nasal spray in patients with perennial nonallergic rhinitis. J Allergy Clin Immunol. 1995 May;95(5 Pt 2):1117-22. [PubMed: 7751528]

33.

Lieberman PL, Settipane RA. Azelastine nasal spray: a review of pharmacology and clinical efficacy in allergic and nonallergic rhinitis. Allergy Asthma Proc. 2003 Mar-Apr;24(2):95-105. [PubMed: 12776442]

34.

Lieberman P. Intranasal antihistamines for allergic rhinitis: mechanism of action. Allergy Asthma Proc. 2009 Jul-Aug;30(4):345-8. [PubMed: 19772756]

35.

Khoueir N, Khalaf MG, Assily R, Rassi S, Hamad WA. Intranasal antihistamines in the treatment of idiopathic non-allergic rhinitis: a systematic review and meta-analysis. Rhinology. 2023 Aug 01;61(4):290-296. [PubMed: 37083127]

36.

Banov CH, Lieberman P., Vasomotor Rhinitis Study Groups. Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. Ann Allergy Asthma Immunol. 2001 Jan;86(1):28-35. [PubMed: 11206234]

37.

Lieberman P, Kaliner MA, Wheeler WJ. Open-label evaluation of azelastine nasal spray in patients with seasonal allergic rhinitis and nonallergic vasomotor rhinitis. Curr Med Res Opin. 2005 Apr;21(4):611-8. [PubMed: 15899111]

38.

Luo X, Ma R, Wu X, Xian D, Li J, Mou Z, Li H. Azelastine enhances the clinical efficacy of glucocorticoid by modulating MKP-1 expression in allergic rhinitis. Eur Arch Otorhinolaryngol. 2015 May;272(5):1165-73. [PubMed: 25060977]

39.

Fokkens W, Hellings P, Segboer C. Capsaicin for Rhinitis. Curr Allergy Asthma Rep. 2016 Aug;16(8):60. [PMC free article: PMC4971034] [PubMed: 27485456]

40.

Gevorgyan A, Segboer C, Gorissen R, van Drunen CM, Fokkens W. Capsaicin for non-allergic rhinitis. Cochrane Database Syst Rev. 2015 Jul 14;2015(7):CD010591. [PMC free article: PMC10669782] [PubMed: 26171907]

41.

Lockey RF. Rhinitis medicamentosa and the stuffy nose. J Allergy Clin Immunol. 2006 Nov;118(5):1017-8. [PubMed: 17088123]

42.

Braun T, Gürkov R, Kramer MF, Krause E. Septal injection of botulinum neurotoxin A for idiopathic rhinitis: a pilot study. Am J Otolaryngol. 2012 Jan-Feb;33(1):64-7. [PubMed: 21419514]

43.

Passàli D, Passàli FM, Damiani V, Passàli GC, Bellussi L. Treatment of inferior turbinate hypertrophy: a randomized clinical trial. Ann Otol Rhinol Laryngol. 2003 Aug;112(8):683-8. [PubMed: 12940665]

44.

Marshak T, Yun WK, Hazout C, Sacks R, Harvey RJ. A systematic review of the evidence base for vidian neurectomy in managing rhinitis. J Laryngol Otol. 2016 Jul;130 Suppl 4:S7-S28. [PubMed: 27488341]

45.

GOLDING-WOOD PH. Observations on petrosal and vidian neurectomy in chronic vasomotor rhinitis. J Laryngol Otol. 1961 Mar;75:232-47. [PubMed: 13706533]

46.

Halderman A, Sindwani R. Surgical management of vasomotor rhinitis: a systematic review. Am J Rhinol Allergy. 2015 Mar-Apr;29(2):128-34. [PubMed: 25785754]

47.

Ma Y, Tan G, Zhao Z, Li W, Huang L, Liu G. Therapeutic effectiveness of endoscopic vidian neurectomy for the treatment of vasomotor rhinitis. Acta Otolaryngol. 2014 Mar;134(3):260-7. [PubMed: 24433056]

48.

Ellegård EK, Karlsson NG, Ellegård LH. Rhinitis in the menstrual cycle, pregnancy, and some endocrine disorders. Clin Allergy Immunol. 2007;19:305-21. [PubMed: 17153022]

49.

Berger WE, Schonfeld JE. Nonallergic rhinitis in children. Curr Allergy Asthma Rep. 2007 May;7(2):112-6. [PubMed: 17437681]

50.

Stammberger H. Surgical treatment of nasal polyps: past, present, and future. Allergy. 1999;54 Suppl 53:7-11. [PubMed: 10442544]

51.

Baroody FM, Gevaert P, Smith PK, Ziaie N, Bernstein JA. Nonallergic Rhinopathy: A Comprehensive Review of Classification, Diagnosis, and Treatment. J Allergy Clin Immunol Pract. 2024 Jun;12(6):1436-1447. [PubMed: 38467330]

52.

Greiwe J, Bernstein JA. Nonallergic Rhinitis: Diagnosis. Immunol Allergy Clin North Am. 2016 May;36(2):289-303. [PubMed: 27083103]

53.

Ellegård EK. Pregnancy rhinitis. Immunol Allergy Clin North Am. 2006 Feb;26(1):119-35, vii. [PubMed: 16443147]

54.

Philpott CM, Robinson AM, Murty GE. Nasal pathophysiology and its relationship to the female ovarian hormones. J Otolaryngol Head Neck Surg. 2008 Aug;37(4):540-6. [PubMed: 19128590]

55.

Hytönen M, Kanerva L, Malmberg H, Martikainen R, Mutanen P, Toikkanen J. The risk of occupational rhinitis. Int Arch Occup Environ Health. 1997;69(6):487-90. [PubMed: 9215937]

56.

Pałczyński C, Walusiak J, Krakowiak A, Szymczak W, Wittczak T, Ruta U, Górski P. Nasal lavage fluid examination in diagnostics of occupational allergy to chloramine. Int J Occup Med Environ Health. 2003;16(3):231-40. [PubMed: 14587536]

57.

Rondón C, Doña I, Torres MJ, Campo P, Blanca M. Evolution of patients with nonallergic rhinitis supports conversion to allergic rhinitis. J Allergy Clin Immunol. 2009 May;123(5):1098-102. [PubMed: 19361848]

58.

Lieberman PL, Smith P. Nonallergic Rhinitis: Treatment. Immunol Allergy Clin North Am. 2016 May;36(2):305-19. [PubMed: 27083104]

59.

Rydén O, Andersson B, Andersson M. Disease perception and social behaviour in persistent rhinitis: a comparison between patients with allergic and nonallergic rhinitis. Allergy. 2004 Apr;59(4):461-4. [PubMed: 15005772]

60.

Levenson T, Greenberger PA. Pathophysiology and therapy for allergic and nonallergic rhinitis: an updated review. Allergy Asthma Proc. 1997 Jul-Aug;18(4):213-20. [PubMed: 9270882]

Disclosure: Bryce Young declares no relevant financial relationships with ineligible companies.

Disclosure: Andrew Sutton declares no relevant financial relationships with ineligible companies.

Disclosure: Zachary Geiger declares no relevant financial relationships with ineligible companies.